Bradley Canino – Guggenheim

Guggenheim

A Guggenheim analyst with 9 tracked ratings across 8 distinct tickers has a 4.3-star track record on the captured sample, achieving a 100% success rate in the second category and issuing 6 bullish ratings out of 7 in the first category.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

10 days ago

2026-05-25 00:00:00+00

Track record

Aggregated

No track record data

Bullish: 17
Hold: 2
Bearish: 0

Aggregated

100% success rate

Bullish: 0
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 1
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
RLAY	2026-05-25	buy	$26.00	Aggregated
CELC	2026-05-15	buy	$165.00	Aggregated
BCAX	2026-05-10	buy	$42.00	Aggregated
NUVL	2026-05-08	buy	$151.00	Aggregated
JANX	2026-05-07	buy	$58.00	Aggregated
ORIC	2026-05-04	buy	$18.00	Aggregated
KYMR	2026-04-30	buy	$125.00	Aggregated
CBIO	2026-04-29	buy	$35.00	Aggregated
SMMT	2026-04-22	buy	$40.00	Aggregated
TYRA	2026-04-15	buy	$54.00	Aggregated
OLMA	2026-03-16	buy	$38.00	Aggregated
CGEM	2026-03-10	buy	$30.00	Aggregated
CGON	2026-02-27	buy	$90.00	Aggregated
CCCC	2026-02-26	buy	$7.00	Aggregated
SNDX	2026-02-26	buy	$34.00	Aggregated
BDTX	2025-12-03	hold	-	Aggregated
SNDX	2025-09-04	buy	$34.00	Aggregated
SNDXSYNDAX PHARMACEUTICALS INC	2025-09-04	unknown	$34.00	Aggregated

Tickers covered(17)

Ticker	Ratings	Last rating	Sources
RLAY	1	2026-05-25	Aggregated
CELC	1	2026-05-15	Aggregated
BCAX	1	2026-05-10	Aggregated
NUVL	1	2026-05-08	Aggregated
JANX	1	2026-05-07	Aggregated
ORIC	1	2026-05-04	Aggregated
KYMR	1	2026-04-30	Aggregated
CBIO	2	2026-04-29	Aggregated
SMMT	1	2026-04-22	Aggregated
TYRA	1	2026-04-15	Aggregated
OLMA	2	2026-03-16	Aggregated
CGEM	1	2026-03-10	Aggregated
CGON	1	2026-02-27	Aggregated
CCCC	1	2026-02-26	Aggregated
SNDX	2	2026-02-26	Aggregated
BDTX	2	2025-12-03	Aggregated
SNDXSYNDAX PHARMACEUTICALS INC	2	2025-09-04	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.